Can switching hormone drugs stall breast cancer when first treatment fails?

NCT ID NCT02738866

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether continuing the drug palbociclib (Ibrance) while switching to a different hormone therapy, fulvestrant (Faslodex), can help control metastatic breast cancer in people whose disease has worsened on palbociclib plus an aromatase inhibitor. The study enrolls 60 adults with hormone receptor-positive, HER2-negative advanced breast cancer. Researchers will measure how long the cancer stays under control and look for genetic mutations that might affect response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Palbociclib (Ibrance) and fulvestrant (Faslodex)
What this could lead to: If successful, this could show that continuing palbociclib with a different hormone therapy helps control metastatic breast cancer for longer after initial treatment stops working.
What could go wrong: This is a small, early-phase trial with only 60 participants. It may not show meaningful benefit, and side effects like low blood cell counts or fatigue are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Show contact details

Locations

Allegheny Health Network (AHN) - Allegheny General Hospital ONLY

Pittsburgh, Pennsylvania, 15212, United States
Anne Arundel Health System Research Institute, Inc.

Annapolis, Maryland, 21401, United States
Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Reading Hospital - McGlinn Cancer Institute

West Reading, Pennsylvania, 19611, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.